IP Library › Patent Application 15938956
Patent Application
App. No. 15/938,956

METHOD FOR TREATING CHRONIC INFLAMMATORY DISEASES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/938,956
Abstract

Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

Claims (14)

1 .- 35 . (canceled)

36 . A method of treating a chronic inflammatory disease, comprising administering to a subject in need thereof an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof.

37 . The method according to claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 100 mg/day, 200 mg/day, 400 mg/day, 800 mg/day or 1000 mg/day.

38 . The method according to claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 100 mg/day.

39 . The method according to claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 200 mg/day.

40 . The method according to claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 400 mg/day.

41 . The method according to claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 800 mg/day.

42 . The method according to claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 1000 mg/day.

43 . The method according to claim 36 , wherein the chronic inflammatory disease is arthritis.

44 . The method according to claim 36 , wherein the chronic inflammatory disease is rheumatoid arthritis.

45 . The method according to claim 36 , wherein the chronic inflammatory disease is osteoarthritis.

46 . The method according to claim 36 , wherein the chronic inflammatory disease is sarcoidosis.

47 . The method according to claim 36 , wherein the chronic inflammatory disease is eczematous dermatitis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2018
From: ZHANG, JINKUN; DZIEWANOWSKA, ZOFIA E.; BELDER, RENE; HENDERSON, IAN; BOGARDUS, JOSEPH B.; ZHANG, ZHAOYING
To: LIGAND PHARMACEUTICALS INC.
Reel/Frame 045798/0138 →